GOTHENBURG, Sweden, April 19 /PRNewswire/ -- Cellectricon, a leading provider of cell-based screening solutions, today announced record sales for the first quarter 2006. The sales increased with 160% compared to the first quarter 2005 making it the company’s best sales result ever.
“We are very pleased with achieving the best sales results ever,” commented Dr. Mattias Karlsson, Chief Operating Officer. “We’ve continue to attract new top-reference customers and experience a growing demand for our micro-scale and cell-based screening systems for drug discovery. The market acceptance for our products is gratifying and our R&D efforts continue to accelerate with several new products in the pipeline scheduled for release later this year and during 2007. We will aggressively address several high growth markets within cell biology and develop innovative solutions to our customers within segments such cell-based screening, transfection and biomedical research.”
The following business developments and sales were significant in the first quarter:
- Record sales of the Dynaflow System a screening and lead optimisation tool for drugs acting on ion channel receptors and safety pharmacology testing. The microfluidic-chip based system is now being used routinely in numerous of key locations and has strong customer validation from 10 of the world’s top 12 pharmaceutical companies.
- A breakthrough order for the newly launched Cellaxess System. Commenting on the order, Professor Hakan Westerblad, Dept. of Physiology and Pharmacology, Karolinska Institutet said, “Thanks to the unique features of the Cellaxess system we are very pleased to incorporate the technology into our research. Since Cellaxess enables electroporation of hard-to-transfect cell types we can now introduce large molecules (proteins, RNA etc) into adult mouse skeletal muscle cells without causing any noticeable damage.”
- Microfabrication Service - Cellectricon’s new business unit offering the company’s unique development expertise and in-house facility for microfabrication. Cellectricon has signed an agreement with Nanoxis AB (www.nanoxis.com) to manufacture their new membrane protein chip.
About Cellectricon
Cellectricon AB (Gothenburg, Sweden) invents and develops new types of functional cell-based screening devices for applications in drug discovery and basic research. The company utilises state of the art interfaces to biological systems by employing novel microfabrication technologies and smart engineering solutions. This enables completely new types of assays and devices with superior performance characteristics and robustness. Cellectricon’s products are designed to enable substantial increases in productivity at the highest data quality. The company was formed in 2000 based on an extensive and solid patent portfolio within different areas such as high-throughput electrophysiology, microfluidics, microfabrication, and electroporation.
Cellectricon AB
CONTACT: Susanne Fagerlund, Communications Manager, Phone:+46-31-760-35-15, susanne.fagerlund@cellectricon.com
